Published in J Gen Virol on December 01, 1990
Mutation of the YXXL endocytosis motif in the cytoplasmic tail of pseudorabies virus gE. J Virol (1999) 2.13
The equine herpesvirus 1 glycoprotein gp21/22a, the herpes simplex virus type 1 gM homolog, is involved in virus penetration and cell-to-cell spread of virions. J Virol (1996) 1.41
Characterization of the regulatory functions of the equine herpesvirus 1 immediate-early gene product. J Virol (1992) 1.25
The equine herpesvirus 1 (EHV-1) UL3 gene, an ICP27 homolog, is necessary for full activation of gene expression directed by an EHV-1 late promoter. J Virol (1993) 1.22
Identification and transcriptional analyses of the UL3 and UL4 genes of equine herpesvirus 1, homologs of the ICP27 and glycoprotein K genes of herpes simplex virus. J Virol (1992) 1.21
Equine herpesvirus 1 glycoprotein D: mapping of the transcript and a neutralization epitope. J Virol (1992) 1.03
Structure-function analysis of the gE-gI complex of feline herpesvirus: mapping of gI domains required for gE-gI interaction, intracellular transport, and cell-to-cell spread. J Virol (1997) 0.99
Analysis of bovine herpesvirus 1 glycoprotein gIV truncations and deletions expressed by recombinant vaccinia viruses. J Virol (1993) 0.89
The glycoprotein D (US6) homolog is not essential for oncogenicity or horizontal transmission of Marek's disease virus. J Virol (1998) 0.88
Identification and initial characterization of the IR6 protein of equine herpesvirus 1. J Virol (1994) 0.84
The highly O-glycosylated glycoprotein gp2 of equine herpesvirus 1 is encoded by gene 71. J Virol (1996) 0.80
The disulfide-bonded structure of feline herpesvirus glycoprotein I. J Virol (1998) 0.76
Expression of equine herpesvirus 1 glycoprotein D by using a recombinant baculovirus. J Virol (1993) 0.75
The Mouse Genome Database (MGD): integrating biology with the genome. Nucleic Acids Res (2004) 8.91
The complete DNA sequence of vaccinia virus. Virology (1990) 7.76
Construction of poxviruses as cloning vectors: insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci U S A (1982) 7.04
Ambient pollution and heart rate variability. Circulation (2000) 6.20
RNA polymerase activity in purified infectious vaccinia virus. Proc Natl Acad Sci U S A (1967) 5.49
Air pollution and incidence of cardiac arrhythmia. Epidemiology (2000) 4.96
Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions. J Biol Chem (1975) 3.66
Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D. Proc Natl Acad Sci U S A (1984) 3.58
Face processing occurs outside the fusiform 'face area' in autism: evidence from functional MRI. Brain (2001) 3.24
Electrophoresis of thymidine kinase activity synthesized by cells transformed by herpes simplex virus. Virology (1972) 3.05
Molecular genetics of vaccinia virus: demonstration of marker rescue. Proc Natl Acad Sci U S A (1982) 3.01
Construction of live vaccines by using genetically engineered poxviruses: biological activity of recombinant vaccinia virus expressing influenza virus hemagglutinin. Proc Natl Acad Sci U S A (1983) 2.79
Two major DNA variants present in serially propagated stocks of the WR strain of vaccinia virus. J Virol (1981) 2.74
A comparison of the caffeine halothane muscle contracture test with the molecular genetic diagnosis of malignant hyperthermia. Anesthesiology (1991) 2.67
Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. Virology (1991) 2.63
Reversal of the interferon-sensitive phenotype of a vaccinia virus lacking E3L by expression of the reovirus S4 gene. J Virol (1995) 2.55
Nucleotide phosphohydrolase in purified vaccinia virus. J Virol (1968) 2.35
A family of structural genes for human lymphoblastoid (leukocyte-type) interferon. Nature (1980) 2.31
Protein kinase and specific phosphate acceptor proteins associated with vaccinia virus cores. J Virol (1972) 2.22
Japanese encephalitis virus-vaccinia recombinants produce particulate forms of the structural membrane proteins and induce high levels of protection against lethal JEV infection. Virology (1991) 2.17
Mice immunized with a subviral particle containing the Japanese encephalitis virus prM/M and E proteins are protected from lethal JEV infection. Virology (1992) 2.15
A total score for the CERAD neuropsychological battery. Neurology (2005) 2.11
Applications of pox virus vectors to vaccination: an update. Proc Natl Acad Sci U S A (1996) 2.10
Modification of the 5'-terminus of mRNA by soluble guanylyl and methyl transferases from vaccinia virus. Proc Natl Acad Sci U S A (1975) 2.10
Immunisation with canarypox virus expressing rabies glycoprotein. Lancet (1992) 2.09
Vaccinia virus host range genes. Virology (1990) 2.02
Analysis and purification of human lymphoblastoid (Namalwa) interferon using a monoclonal antibody. J Gen Virol (1982) 2.01
Cloning, nucleotide sequencing, and expression of tetanus toxin fragment C in Escherichia coli. J Bacteriol (1986) 2.00
HIV-1 recombinant poxvirus vaccine induces cross-protection against HIV-2 challenge in rhesus macaques. Nat Med (1995) 1.99
Recombinant vaccine-induced protection against the highly pathogenic simian immunodeficiency virus SIV(mac251): dependence on route of challenge exposure. J Virol (1998) 1.98
An update on the vaccinia virus genome. Virology (1993) 1.95
X-chromosome effects on female brain: a magnetic resonance imaging study of Turner's syndrome. Lancet (1993) 1.93
Cloning and expression of foreign genes in vaccinia virus, using a host range selection system. J Virol (1989) 1.84
TAR RNA-binding protein is an inhibitor of the interferon-induced protein kinase PKR. Proc Natl Acad Sci U S A (1994) 1.80
Polyadenylate polymerase from vaccinia virions. Nat New Biol (1973) 1.76
Two nucleic acid-dependent nucleoside triphosphate phosphohydrolases from vaccinia virus. Nucleotide substrate and polynucleotide cofactor specificities. J Biol Chem (1974) 1.76
Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology (1992) 1.76
Measures of twin concordance. Acta Genet Stat Med (1967) 1.69
Efficacy of nucleoprotein and haemagglutinin antigens expressed in fowlpox virus as vaccine for influenza in chickens. Vaccine (1991) 1.66
Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis (1998) 1.64
Recombinant vaccinia virus: immunization against multiple pathogens. Science (1985) 1.60
Mapping of a gene for severe pediatric gastroesophageal reflux to chromosome 13q14. JAMA (2000) 1.56
Recombinant fowlpox virus inducing protective immunity in non-avian species. Vaccine (1988) 1.55
Comparison of protective immunity elicited by recombinant vaccinia viruses that synthesize E or NS1 of Japanese encephalitis virus. Virology (1991) 1.55
Host-range restriction of vaccinia virus E3L-specific deletion mutants. Virus Genes (1996) 1.53
Transcriptional complexity of vaccinia virus in vivo and in vitro. J Virol (1977) 1.53
Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl Cancer Inst (1997) 1.52
Nonreplicating viral vectors as potential vaccines: recombinant canarypox virus expressing measles virus fusion (F) and hemagglutinin (HA) glycoproteins. Virology (1992) 1.48
High molecular weight virion-associated RNA of vaccinia. A possible precursor to 8 to 12 S mRNA. J Biol Chem (1977) 1.45
Recombinant vaccinia viruses co-expressing dengue-1 glycoproteins prM and E induce neutralizing antibodies in mice. Vaccine (1994) 1.43
An upper limit on the stochastic gravitational-wave background of cosmological origin. Nature (2009) 1.42
Characterization of indoor particle sources: A study conducted in the metropolitan Boston area. Environ Health Perspect (2000) 1.41
A blinded comparison of noninvasive, in vivo phosphorus nuclear magnetic resonance spectroscopy and the in vitro halothane/caffeine contracture test in the evaluation of malignant hyperthermia susceptibility. Anesth Analg (1991) 1.39
Role of the vaccinia virus E3L and K3L gene products in rescue of VSV and EMCV from the effects of IFN-alpha. J Interferon Cytokine Res (1998) 1.38
Microtia reconstruction: does the cartilage framework grow? Plast Reconstr Surg (1989) 1.38
Nitric oxide inhibits viral replication in murine myocarditis. J Clin Invest (1996) 1.36
Distinct patterns of IFN sensitivity observed in cells infected with vaccinia K3L- and E3L- mutant viruses. Virology (1995) 1.36
Vaccinia virus rifampicin-resistance locus specifies a late 63,000 Da gene product. Virology (1986) 1.35
Protective immunity against avian influenza induced by a fowlpox virus recombinant. Vaccine (1988) 1.35
Atypical patterns of cerebral motor activation in autism: a functional magnetic resonance study. Biol Psychiatry (2001) 1.35
Deletion of 55 open reading frames from the termini of vaccinia virus. Virology (1991) 1.34
Investigation of the active site of papain with fluorescent probes. Biochem J (1973) 1.30
Fowlpox virus as a vector in non-avian species. Vaccine (1988) 1.29
Recombinant vaccinia virus expression of the bovine leukaemia virus envelope gene and protection of immunized sheep against infection. Vaccine (1991) 1.28
Poxvirus-based vaccine candidates for cancer, AIDS, and other infectious diseases. J Leukoc Biol (1995) 1.27
Imaging features of intraosseous ganglia: a report of 45 cases. Eur Radiol (2004) 1.26
Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis (1995) 1.26
Method comparisons for particulate nitrate, elemental carbon, and PM2.5 mass in seven U.S. cities. J Air Waste Manag Assoc (2000) 1.25
Potential use of non-replicating vectors as recombinant vaccines. Vaccine (1992) 1.25
Vaccinia virus as an expression vector. Methods Enzymol (1987) 1.25
Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge. J Virol (1991) 1.24
A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine. Virology (1992) 1.24
M protein (M1) of influenza virus: antigenic analysis and intracellular localization with monoclonal antibodies. J Virol (1989) 1.24
Molecular complexity of vaccinia DNA and the presence of reiterated sequences in the genome. Virology (1977) 1.23
A 31-residue tryptic peptide from the active site of the [Ca++]-transporting adenosine triphosphatase of rabbit sarcoplasmic reticulum. FEBS Lett (1976) 1.22
Physical mapping and DNA sequence analysis of the rifampicin resistance locus in vaccinia virus. Virology (1985) 1.22
Complete amino acids sequence of a variant surface glycoprotein (VSG 117) from Trypanosoma brucei. J Mol Biol (1982) 1.21
NYVAC-Pf7: a poxvirus-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Infect Immun (1996) 1.20
Efficacy studies on a canarypox-rabies recombinant virus. Vaccine (1991) 1.20
Vaccinia: virus, vector, vaccine. Adv Virus Res (1988) 1.19
In vitro synthesis of a high molecular weight virion-associated RNA by vaccinia. J Biol Chem (1977) 1.17
Aglossia-adactylia syndrome. J Med Genet (1975) 1.17
Multiple immunizations with attenuated poxvirus HIV type 2 recombinants and subunit boosts required for protection of rhesus macaques. AIDS Res Hum Retroviruses (1996) 1.16
Fusogenic segments of bovine leukemia virus and simian immunodeficiency virus are interchangeable and mediate fusion by means of oblique insertion in the lipid bilayer of their target cells. Proc Natl Acad Sci U S A (1992) 1.16
Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine (1995) 1.15
Prediction and preparation, fundamental functions of the cerebellum. Learn Mem (1999) 1.14
Single-stranded deoxyribonucleic acid-specific nuclease from vaccinia virus. Purification and characterization. J Biol Chem (1974) 1.14
Immunogenicity and protective efficacy of a human immunodeficiency virus type 2 recombinant canarypox (ALVAC) vaccine candidate in cynomolgus monkeys. J Infect Dis (1996) 1.13
Newcastle disease virus fusion protein expressed in a fowlpox virus recombinant confers protection in chickens. J Virol (1990) 1.11
p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge. Proc Natl Acad Sci U S A (1996) 1.11
In defense of Dr. Protopappas: the anesthesiologist's concerns related to the practice of sedation and local and general anesthesia. Anesth Prog (1990) 1.07
Effects of subcutaneous calcitriol administration on plasma calcium and parathyroid hormone concentrations in continuous ambulatory peritoneal dialysis uremic patients. Perit Dial Int (1993) 1.07
Structure and properties of human interferon-alpha from Namalwa lymphoblastoid cells. Biochem J (1982) 1.07
Mutations in ORF D13L and other genetic loci alter the rifampicin phenotype of vaccinia virus. Virology (1993) 1.06
Poxvirus-based vectors as vaccine candidates. Crit Rev Immunol (1990) 1.05
A DNA ligase gene in the Copenhagen strain of vaccinia virus is nonessential for viral replication and recombination. Virology (1990) 1.05
Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization. Eur J Immunol (1996) 1.04